train
(N=92)
validation
(N=102)
P-value
Age(years)
Mean (SD) 63.3 (7.91) 64.1 (8.33) 0.737
Median [Min, Max] 64.5 [35.0, 76.0] 66.0 [33.0, 80.0]
Sex
FeMale 10 (10.9%) 11 (10.8%) 1
Male 82 (89.1%) 91 (89.2%)
Smoking
No 16 (17.4%) 32 (31.4%) 0.0369
Yes 76 (82.6%) 70 (68.6%)
Pathologic subtype
Non squamous 48 (52.2%) 58 (56.9%) 0.61
Squamous 44 (47.8%) 44 (43.1%)
PFS(months)
Mean (SD) 15.3 (10.6) 13.4 (6.44) 0.291
Median [Min, Max] 12.5 [0.600, 37.4] 13.1 [0.367, 27.9]
OS(months)
Mean (SD) 20.7 (10.7) 14.5 (6.47) 0.285
Median [Min, Max] 20.9 [1.33, 39.3] 14.8 [0.367, 27.9]
PD-L1 TPS group
<1% 11 (12.0%) 9 (8.8%) 0.596
1-50% 19 (20.7%) 16 (15.7%)
>=50% 12 (13.0%) 18 (17.6%)
Missing 50 (54.3%) 59 (57.8%)
Clinical benefit
DCB 69 (75.0%) 89 (87.3%) 0.039
NDB 23 (25.0%) 12 (11.8%)
Unknown 0 (0%) 1 (1.0%)
LDH
Mean (SD) 241 (160) 242 (189) 0.702
Median [Min, Max] 189 [66.7, 1110] 193 [96.0, 1660]
Missing 1 (1.1%) 5 (4.9%)
NLR
Mean (SD) 3.84 (2.05) 4.05 (2.74) 0.38
Median [Min, Max] 3.37 [1.04, 9.80] 3.30 [1.15, 16.3]
Missing 0 (0%) 2 (2.0%)
Bone metastasis
No 59 (64.1%) 51 (50.0%) 0.066
Yes 33 (35.9%) 51 (50.0%)
Brain metastasis
No 76 (82.6%) 86 (84.3%) 0.9
Yes 16 (17.4%) 16 (15.7%)
Liver metastasis
No 84 (91.3%) 83 (81.4%) 0.0738
Yes 8 (8.7%) 19 (18.6%)
Pleura metastasis
No 69 (75.0%) 71 (69.6%) 0.499
Yes 23 (25.0%) 31 (30.4%)
Lymph metastasis
No 46 (50.0%) 36 (35.3%) 0.0542
Yes 46 (50.0%) 66 (64.7%)